


Canadian Consortium on Neurodegeneration in Aging (CCNA)

 consortiapedia.fastercures.org/consortia/ccna/

Research Areas

 **Biomarker Research**

 **Basic Research**

At a Glance

- Status: **Active Consortium**
- Year Launched: **2014**
- Initiating Organization: **Canadian Institutes of Health Research**
- Initiator Type: **Government**
- Location: **North America**

Abstract

The Canadian Consortium on Neurodegeneration in Aging (CCNA) focuses on research into the basic mechanisms of neurodegenerative diseases, accelerating the development of tools that can be used to assist in the diagnosis and treatment of the diseases. The intended outcome of these tools is to improve the quality of life and services for patients with neurodegenerative diseases.

Mission

As part of the Canadian contribution to the International Collaborative Research Strategy for Alzheimer's disease, CCNA brings together Canadian government agencies (federal and provincial), foundations, pharmaceutical companies, philanthropists, and international stakeholders to identify whether there are common causes and risk factors to neurodegenerative diseases.

Structure & Governance



CCNA will be led by one nominated principal investigator, supported by three principal investigators for each of the three research themes: Primary Prevention, Secondary Prevention, and Quality of Life.

Financing

The consortium receives C\$31.5 million from the federal government and several partners (such as the Alzheimer Society of Canada, which contributes C\$4.0 million), as well as an additional C\$24.0 million from partners in Ontario and Quebec.

Intellectual Property

Intellectual property guidelines follow those for any grant issued by the Canadian Institutes of Health Research (CIHR). Specifically, CIHR does not retain or claim any ownership of, or exploitation or proprietary rights to, intellectual property, copyright, or inventions developed/resulting from research supported with grant funds and does not pass judgment on the eventual commercial success of the research.

Should grantees decide to pursue commercialization of any results of the research, including all partnered initiatives, they must adhere to institutional and CIHR policies governing the assignment of intellectual property.

Patent Engagement

The Alzheimer Society of Canada and Alzheimer's Research UK are founders and financial contributors to the consortium.

Links/Social Media Feed

Homepage

<http://www.cihr.gc.ca/e/46475.html>

Points of Contact

Joanne Goldberg
Assistant Director
CIHR Institute of Aging
phone: 514-360-2433
email: joanne.goldberg@criugm.qc.ca

Michelle Peel
Assistant Director
CIHR Institute of Aging
phone: 613-952-4537
email: michelle.peel@cihr-irsc.gc.ca

Sponsors & Partners

Alberta Prion Research Institute
Alzheimer Society of Canada
Alzheimer's Research UK
Canadian Institutes of Health Research
Canadian Nurses Foundation
Fonds de recherche du Québec - Santé
International Collaborative Research Strategy for
Alzheimer's Disease
Michael Smith Foundation for Health Research
Ontario Brain Institute
Pfizer, Inc.
Robin and Barry Picov Foundation
Sanofi S.A.
The New Brunswick Health Research Foundation
The Nova Scotia Health Research Foundation
The Saskatchewan Health Research Foundation
Women's Brain Health Initiative

Updated: 04/07/2016